New Mexico Educational Retirement Board cut its holdings in Amgen, Inc. (NASDAQ:AMGN) by 3.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 53,145 shares of the medical research company’s stock after selling 2,000 shares during the period. New Mexico Educational Retirement Board’s holdings in Amgen were worth $10,096,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of AMGN. Leavell Investment Management Inc. increased its stake in Amgen by 0.8% in the 1st quarter. Leavell Investment Management Inc. now owns 10,720 shares of the medical research company’s stock worth $2,037,000 after acquiring an additional 80 shares during the last quarter. American Research & Management Co. increased its stake in Amgen by 21.0% in the 1st quarter. American Research & Management Co. now owns 5,764 shares of the medical research company’s stock worth $1,095,000 after acquiring an additional 1,000 shares during the last quarter. Founders Capital Management LLC increased its stake in Amgen by 59.4% in the 1st quarter. Founders Capital Management LLC now owns 14,979 shares of the medical research company’s stock worth $2,846,000 after acquiring an additional 5,580 shares during the last quarter. Asset Advisors Investment Management LLC increased its stake in Amgen by 0.6% in the 1st quarter. Asset Advisors Investment Management LLC now owns 26,192 shares of the medical research company’s stock worth $4,976,000 after acquiring an additional 161 shares during the last quarter. Finally, Spectrum Management Group Inc. increased its stake in Amgen by 77,537.5% in the 1st quarter. Spectrum Management Group Inc. now owns 12,422 shares of the medical research company’s stock worth $2,360,000 after acquiring an additional 12,406 shares during the last quarter. 80.65% of the stock is currently owned by institutional investors.
A number of research firms have issued reports on AMGN. Zacks Investment Research downgraded Amgen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 23rd. Oppenheimer set a $224.00 price objective on Amgen and gave the stock a “buy” rating in a research note on Sunday, January 27th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $190.00 price objective on shares of Amgen in a research note on Wednesday, January 30th. Leerink Swann reduced their price objective on Amgen from $200.00 to $192.00 and set a “market perform” rating on the stock in a research note on Wednesday, January 30th. Finally, Mizuho set a $208.00 price objective on Amgen and gave the stock a “buy” rating in a research note on Friday, April 12th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the stock. Amgen presently has an average rating of “Hold” and a consensus target price of $208.84.
NASDAQ AMGN opened at $169.91 on Friday. The company has a market cap of $103.63 billion, a PE ratio of 11.80, a P/E/G ratio of 2.24 and a beta of 1.15. The company has a debt-to-equity ratio of 2.71, a quick ratio of 2.53 and a current ratio of 2.77. Amgen, Inc. has a fifty-two week low of $166.30 and a fifty-two week high of $210.19.
Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, April 30th. The medical research company reported $3.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.45 by $0.11. The firm had revenue of $5.56 billion for the quarter, compared to the consensus estimate of $5.55 billion. Amgen had a return on equity of 71.02% and a net margin of 34.00%. The company’s revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.47 EPS. On average, equities analysts expect that Amgen, Inc. will post 13.94 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a dividend yield of 3.41%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is currently 40.28%.
In other news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $193.18, for a total transaction of $386,360.00. Following the transaction, the director now owns 15,092 shares of the company’s stock, valued at approximately $2,915,472.56. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 6,000 shares of company stock worth $1,115,580. Corporate insiders own 0.25% of the company’s stock.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Story: Quiet Period Expirations
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.